Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.71 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.71 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14254985 | 1.00 | HDAC1 (0.71) | HDAC1HDAC2HDAC11HDAC8HDAC6 | |
| SCHEMBL14254994 | 0.89 | HDAC4 (0.66) | HDAC1HDAC2HDAC11HDAC8HDAC6 | |
| SCHEMBL8363260 | 0.89 | HDAC4 (0.66) | HDAC1HDAC2HDAC11HDAC8HDAC6 | |
| SCHEMBL14254988 | 0.89 | HDAC1 (0.61) | HDAC1HDAC2HDAC11HDAC8HDAC6 | |
| SCHEMBL14254913 | 0.89 | HDAC1 (0.61) | HDAC1HDAC2HDAC11HDAC8HDAC6 | |
| SCHEMBL8271583 | 0.88 | HDAC2 (0.68) | HDAC1HDAC2HDAC11HDAC8HDAC6 | |
| SCHEMBL28316169 | 0.86 | HDAC1 (0.59) | HDAC1HDAC2HDAC11HDAC8HDAC6 | |
| SCHEMBL5130136 | 0.86 | HDAC1 (0.59) | HDAC1HDAC2HDAC11HDAC8HDAC6 | |
| SCHEMBL8269739 | 0.85 | HDAC2 (0.65) | HDAC1HDAC2HDAC11HDAC8HDAC6 | |
| SCHEMBL14254912 | 0.84 | HDAC1 (0.57) | HDAC1HDAC2HDAC11HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1443928-B1 | TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER OF THE BRAIN | SLOAN KETTERING INST CANCER (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100048608-A1 | Histone Deacetylase Inhibitors for the Treatment of Ocular Neovascular or Edematous Disorders and Diseases | ALCON, INC. (CH) | 2010-02-25 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| WO-2004043352-A2 | HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF OCULAR NEOVASCULAR OR EDEMATOUS DISORDERS AND DISEASES | ALCON, INC. (CH) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003032921-A2 | TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER OF THE BRAIN | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC1 3/4885HDAC2 13/4885HDAC11 10/4885 |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC1 3/4885HDAC2 13/4885HDAC11 10/4885 |
| US-20100048608-A1 | Histone Deacetylase Inhibitors for the Treatment of Ocular Neovascular or Edematous Disorders and Diseases | HDAC1, HDAC3, HDAC5 | HDAC1 1/4885HDAC2 8/4885HDAC11 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.